Nanopharmaceuticals are novel medicine with particle size less than 1 micron, which work on the principle of nanotechnology. Nanopharmaceuticals are widely used in drug delivery as a carrier for therapeutic compound or as a therapeutic compound. Nanopharmaceuticals are designed to target particular cells, tissue or a specific organ.
Market Dynamics
Increasing prevalence of cardiovascular diseases, cancer, and infectious diseases are major factors driving nanopharmaceuticals market growth. The World Health Organization, factsheet September 2018, estimated around 10 million cases of tuberculosis and around 1.6 million deaths from the disease in 2017. Moreover, advantages of nanopharmaceuticals over macroscopic level medicines is expected to boost the market growth. Nanopharmaceuticals can pass the blood brain barrier and can access the remote areas of brain as well as low solubility of the compound can be developed for enhancing its characteristics.
Key features of the study:
- This report provides in-depth analysis of the nanopharmaceuticals market and provides market size (US$ million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
- It profiles key players in the global nanopharmaceuticals market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include, Abbott, GlaxoSmithKline and plc., Eli Lilly and Company, Astrazeneca plc., Novavax, Inc., Stryker Corporation, OSI Pharmaceuticals, Kadmon Pharmaceuticals, Samyang Biopharm, Mitsubishi Tanabe Pharma Corporation, Kaken Pharmaceutical, Selecta Biosciences, Par Pharmaceutical, Cerulean Pharma Inc., Navidea Biopharmaceuticals, Inc., AbbVie Inc., AMAG Pharmaceuticals, Amgen Inc., Astellas Pharma Inc., Celgene Corporation, Gilead Sciences, Inc., JOHNSON & JOHNSON, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Hoffmann-La Roche AG, Sanofi S.A, Shire Plc., and Teva Pharmaceuticals Industries Limited.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics.
- The global nanopharmaceuticals market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the nanopharmaceuticals market
Detailed Segmentation:
- Global Nanopharmaceuticals Market, By Carrier:
- Liposomes
- Polymer
- Nanocrystals
- Inorganic
- Protein
- Others
- Global Nanopharmaceuticals Market, By Application:
- Oncology
- Neurology
- Anti-inflammatory
- Anti-infective
- Cardiovascular
- Others
- Global Nanopharmaceuticals Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Nanopharmaceuticals Market, By Geography:
- North America
- By Carrier:
- Liposomes
- Polymer
- Nanocrystals
- Inorganic
- Protein
- Others
- By Application:
- Oncology
- Neurology
- Anti-inflammatory
- Anti-infective
- Cardiovascular
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Latin America
- By Carrier:
- Liposomes
- Polymer
- Nanocrystals
- Inorganic
- Protein
- Others
- By Application:
- Oncology
- Neurology
- Anti-inflammatory
- Anti-infective
- Cardiovascular
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Carrier:
- Liposomes
- Polymer
- Nanocrystals
- Inorganic
- Protein
- Others
- By Application:
- Oncology
- Neurology
- Anti-inflammatory
- Anti-infective
- Cardiovascular
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Carrier:
- Liposomes
- Polymer
- Nanocrystals
- Inorganic
- Protein
- Others
- By Application:
- Oncology
- Neurology
- Anti-inflammatory
- Anti-infective
- Cardiovascular
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Carrier:
- Liposomes
- Polymer
- Nanocrystals
- Inorganic
- Protein
- Others
- By Application:
- Oncology
- Neurology
- Anti-inflammatory
- Anti-infective
- Cardiovascular
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Carrier:
- Liposomes
- Polymer
- Nanocrystals
- Inorganic
- Protein
- Others
- By Application:
- Oncology
- Neurology
- Anti-inflammatory
- Anti-infective
- Cardiovascular
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Abbott *
- Company Overview
- Product Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- GlaxoSmithKline plc.
- Eli Lilly and Company
- Astrazeneca plc.
- Novavax, Inc.
- Stryker Corporation
- OSI Pharmaceuticals
- Kadmon Pharmaceuticals
- Samyang Biopharm
- Mitsubishi Tanabe Pharma Corporation
- Kaken Pharmaceutical
- Selecta Biosciences
- Par Pharmaceutical
- Cerulean Pharma Inc.
- Navidea Biopharmaceuticals
- AbbVie Inc.
- AMAG Pharmaceuticals
- Amgen Inc.
- Astellas Pharma Inc.
- Celgene Corporation
- Gilead Sciences, Inc.
- JOHNSON & JOHNSON
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- Hoffmann-La Roche AG
- Sanofi S.A
- Shire Plc.
- Teva Pharmaceuticals Industries Limited.
“*” marked represents similar segmentation in other categories in the respective section.
